CJC-1295 / Ipamorelin

Choose a three-month supply for a consistent peptide protocol centered on growth-hormone signaling.

How it is intended to work: CJC-1295 is designed to mimic growth-hormone-releasing hormone, while ipamorelin is designed to trigger growth-hormone release through another receptor. The combination is promoted for recovery, sleep, lean-mass, and fat-reduction goals.

What to expect: Your clinician should confirm the concentration, schedule, pharmacy, supplies, and monitoring plan for the full 90-day course. Screening should address cancer history, blood-sugar control, swelling, sleep apnea, pregnancy, and other medications. Monitoring may include glucose and IGF-1.